Jun 16, 2026 05:17AM
Jun 15, 2026 07:49AM
Jun 15, 2026 07:45AM
May 15, 2026 05:00PM
Apr 22, 2026 07:30AM
Apr 22, 2026 07:30AM
Apr 1, 2026 07:45AM TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Mar 24, 2026 10:30AM
Mar 23, 2026 07:45AM
Mar 23, 2026 07:45AM
Feb 17, 2026 07:46AM
Feb 17, 2026 07:45AM
Feb 2, 2026 07:45AM
Feb 2, 2026 07:45AM TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
Dec 11, 2025 07:30AM
Dec 11, 2025 07:30AM
Nov 14, 2025 07:00AM
Aug 14, 2025 04:15PM
Jun 30, 2025 06:52AM
Jun 24, 2025 08:04AM
Jun 24, 2025 08:00AM TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Car
Jun 23, 2025 09:16AM
Jun 9, 2025 10:12AM
Jun 9, 2025 08:01AM
Jun 9, 2025 08:00AM
Jun 3, 2025 10:00AM
Jun 3, 2025 09:58AM
Jun 2, 2025 08:03AM TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
May 15, 2025 04:10PM
May 13, 2025 08:00AM
May 5, 2025 08:06AM
May 5, 2025 08:00AM
Apr 1, 2025 08:00AM
Mar 11, 2025 08:05AM
Nov 25, 2024 08:39AM TuHURA Biosciences (HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma
Nov 25, 2024 08:35AM
Oct 17, 2024 04:38PM
Oct 17, 2024 04:35PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All